$HROW Cashflow Statement | Understand Stock

$HROW

$28.94 -$0.02 (0.05%) Live

$HROW Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss (including noncontrolling interests)
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization of property, plant and equipment and software development costs
Amortization of intangible assets
Non-cash lease expense
Acquisition of Melt Pharmaceuticals
Provision for credit losses
Amortization of debt issuance costs and debt discount
Gain on forgiveness of PPP loan
Investment loss (gain) from investment in Eton
Equity in losses of unconsolidated entities
Loss on early extinguishment of loan
Impairment of long-lived assets
Loss on disposal of equipment
Impairment of intangible assets
Loss on extinguishment of debt
Stock-based compensation
Gain on sale of non-ophthalmology assets
Changes in assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable, accrued expenses, accrued rebates and copay assistance
Accrued payroll and related liabilities
Deferred revenue and customer deposits

NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES

CASH FLOWS FROM INVESTING ACTIVITIES
Net proceeds from sale of investments
Issuance of note receivable, Melt Pharmaceuticals
Proceeds from sale of non-ophthalmology assets
Net proceeds on sale of investment in Eton Pharmaceuticals
Acquisition of Melt Pharmaceuticals
Investment in patent and trademark assets
Purchase of licenses, product NDAs and patents
Proceeds from sale of property, plant and equipment
Purchase of product NDAs, marketing authorizations and patents
Purchase of product rights and related patents
Purchases of property, plant and equipment
NET CASH USED IN INVESTING ACTIVITIES

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from 11.875% notes payable, net of costs
Principal and exit fee payments on SWK loan
Net proceeds from 11.875% notes payable, net of costs
Proceeds from Oaktree credit facility debt, net of costs
Net proceeds from public offering
Payments on finance lease obligations
Proceeds from new debt, net of costs
Repayment of notes payable, inclusive of costs
Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options
Proceeds from exercise of stock options
Sale of preferred stock, net of discount and issuance costs
Repayment of preferred stock
Payment of preferred stock dividends
Proceeds from B Riley senior secured note, net of costs
Payment of debt issuance costs
Proceeds from public offering of common stock, net of offering costs
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES

NET CHANGE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, beginning of period
CASH AND CASH EQUIVALENTS, end of period
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accrual of milestone payment
Reclassification of deferred financing costs
Accrual of exit fee related to Oaktree Loan
Purchase of property, plant and equipment included in accounts payable and accrued expenses
Change in right-of-use assets for operating lease obligations assumptions
Right-of-use assets obtained in exchange for new operating lease obligations
Net reduction in right-of-use assets and lease obligations due to modification
Melt accounts receivable transferred to note receivable
Reclass of deferred commitment fees from prepaid expenses into debt issuance costs
Insurance premium financed
Purchase of intangible asset included in accounts payable and accrued expenses

Comments